Successfully reported this slideshow.

NCCTG Overall Organization - Grothey

533 views

Published on

  • Be the first to comment

  • Be the first to like this

NCCTG Overall Organization - Grothey

  1. 1. Patient Advocacy Symposium June 9, 2008 Axel Grothey, MD Group Vice Chair
  2. 2. CP1223393-2 3 Trial design and conduct • To improve clinical trial design and conduct 1 Improved therapeutics • To improve the duration and quality of life of cancer patients Specific Aims 22 Translational research • To improve the understanding of cancer biology and the biological consequences of treatment 4 Cancer prevention and control • To provide an infrastructure for studies of cancer prevention and symptom management
  3. 3. CP1223393-3 Idea Generators NCCTG Programs NCCTG Leadership NCCTG Organizational Overview MCCC and other academic centers Cooperative groups Industry NCI Community Oncologists Community Oncology Programs
  4. 4. CP1223393-4 Community-Based Partnership
  5. 5. NCCTG in 1977 WA OR ID MT Saskatchewan WY UTNV CA AZ NM CO NE SD ND MN MOKS FL NC MI KY OH VA PA NY ME NHVT IA IL WI Ontario Mexico GA TX LA AR AL TN MS OK SC IN WV AK MD DE NJ CT RI MA PR HI DC
  6. 6. CP1223393-6 The 43 NCCTG Memberships AreThe 43 NCCTG Memberships Are Headquartered in 28 States & CanadaHeadquartered in 28 States & Canada AK HI PR WA OR ID MT Saskatchewan WY UTNV CA AZ NM CO NE SD ND MN MOKS FL NC MI KY WV VA PA NY MD DE NJ CT RI MA ME NHVT IA IL WI DC GA TX LA AR AL TN MS OK SC IN OH
  7. 7. CP1223393-7 NCCTG has >340 treating locations in 33NCCTG has >340 treating locations in 33 states as well as Canada & Puerto Ricostates as well as Canada & Puerto Rico (Pending/newly approved treating locations in red states) AK WA OR ID MT Saskatchewan W Y UTNV CA AZ NM CO NE SD ND MN MOKS FL NC MI KY OH VA PA NY MD DE NJ CT RI MA ME NHVT IA 19 12 5 6 3 IL WI DC 37 25 17 45 2 42 5 2 4 HI GA10 TX LA AR AL TN MS OK 2 2 6 1 16 SC3 IN 1 14 9 16 WV 1 PR 21 1 1 2 2 2 2 4 AK WA OR ID MT Saskatchewan W Y UTNV CA AZ NM CO NE SD ND MN MOKS FL NC MI KY OH VA PA NY MD DE NJ CT RI MA ME NHVT IA 19 12 5 6 3 IL WI DC 37 25 17 45 2 42 5 2 4 HI GA10 TX LA AR AL TN MS OK 2 2 6 1 16 SC3 IN 1 14 9 16 WV 1 PR 21 1 1 2 2 2 2 4 AK WA OR ID MT Saskatchewan W Y UTNV CA AZ NM CO NE SD ND MN MOKS FL NC MI KY OH VA PA NY MD DE NJ CT RI MA ME NHVT IA 19 12 5 6 3 IL WI DC 37 25 17 45 2 42 5 2 4 HI GA10 TX LA AR AL TN MS OK 2 2 6 1 16 SC3 IN 1 14 9 16 WV 1 PR 21 1 1 2 2 2 2 4 AK WA OR ID MT Saskatchewan WY UTNV CA AZ NM CO NE SD ND MN MOKS FL NC MI KY OH VA PA NY MD DE NJ CT RI MA ME NHVT IA 19 12 5 6 3 IL WI DC 37 25 17 45 2 42 5 2 4 HI GA10 TX LA AR AL TN MS OK 2 2 6 1 16 SC3 IN 1 14 9 16 WV 1 PR 21 1 1 2 2 2 2 4
  8. 8. 8 New members since last meeting • Keith Lanier, MD – Columbia River CCOP, Portland, OR • Meera Ravidranathan, MD – New Mexico MBCCOP, Richmond, VA • Mary Helen Hackney, MD – Virginia Commonwealth MBCCOP, Richmond, VA • Marianne Lange, MD – Grand Rapids Clinical Oncology Program, Grand Rapids, MI • Jacqueline Vuky, MD – Virginia Mason Research Center CCOP, Seattle, WA
  9. 9. CP1223393-9 Membership and Governance Membership • 32 CCOPs • 11 Non-CCOPs Executive Committee Membership PI and Modality Co-Chairs • Chair: J. Kugler – Peoria, IL • Vice Chair: P. Stella – Ann Arbor, MI
  10. 10. CP1223393-10 Membership and Governance Membership • 32 CCOPs • 11 Non-CCOPs Executive Committee Membership PI and Modality Co-Chairs • Chair: J. Kugler – Peoria, IL • Vice Chair: P. Stella – Ann Arbor, MI
  11. 11. CP1223393-11 Community Member Involvement • Co-Chairs of scientific committees • Participate in protocol review • Co-chairs of protocols • Audits • Patient Advocate Network
  12. 12. CP1223393-12 Community Accrual and Data Quality • 78% of NCCTG accrual from the community • Every NCCTG coordinated trial in last grant period opened and accrued patients at a community site • Since 2003: 60 audits; 1 unacceptable
  13. 13. 13 ASCO Community Participation Award Nominees 2008 Preston D. Steen, M.D. MeritCare Hospital CCOP Fargo, ND Roscoe F. Morton, M.D. Iowa Oncology Research Association CCOP Des Moines, IA
  14. 14. CP1223393-14 NCCTG Organizational Overview NCCTG Leadership Idea Generators Clinical data Biospecimens MCCC and other academic centers Cooperative groups Industry NCI Community Oncologists Community Oncology Programs
  15. 15. CP1223393-15 Mayo Clinic Cancer Center • Leadership • Integrated systems • Financial support
  16. 16. CP1223393-16 Mayo Clinic Cancer Center • Leadership • Integrated systems • Financial support
  17. 17. CP1223393-17 Mayo Clinic Cancer Center • Leadership • Integrated systems • Financial support
  18. 18. NCCTG Committees Discipline-Oriented Scientific • Cancer Control • Novel Therapeutics • Quality of Life Modality • Pathology • Radiation Oncology • Surgery Core Function • Audit • Cancer Health Disparity • Oncology Nursing • Clinical Research Assoc Board • Patient Advocates Statistics and Data Center • Biostatistics Advisory • Translational Research Coord Loprinzi Martenson Jatoi Brown Goetz Erlichman Adjei Galanis Halyard Grothey Jatoi Brown Visscher Smyrk Aubry Scheithauer Halyard Martenson Schild Brown Pockaj Cima Nichols New Perotti Pearson Garces Leitch Greder Finck DeKrey Kowbell Mahacek Barnick Rogers Dillavou Smith DeLucca Keller Buckmeier Dueck Sargent Mandrekar Ballman Goetz Sinicrope Molina Jenkins Breast Gastrointestinal Lung Neuro-oncology Disease Specific LIAISONS
  19. 19. CP1223393-19 Protocol Activity 2001-2005 NCCTG-led 61 • Actively accruing 28 • In development 24 • Closed, in follow up 103 NCCTG-endorsed 65
  20. 20. CP1223393-20 Accrual to NCCTG Trials 2001-2005 NCCTG-led • Patients 8,631 • NCCTG member accrual 3,952 NCCTG-endorsed • NCCTG member accrual 3,307
  21. 21. CP1223393-21 NCCTG Manuscripts – 2001-2006 (Published and Accepted) Total 217 • NEJM 5 • JNCI 4 • JCO 60
  22. 22. CP1223393-22 Abstracts and Presentations ASCO 2001-2007 Total 229 • Plenary 2 • Oral 63 • Poster discussion 66 • Poster 80 • Publication 18
  23. 23. CP1223393-23 ASCO Abstracts 2008 Oral Poster Discussion Poster Publication Pending 10 9 14 11 17 16 6 6 2 0 49 42 Numbers in red are NCCTG-Led
  24. 24. 24 ASCO Abstracts 2008 Brain Breast Cancer Control GI Lung Novel Therapeutics QOL Statistical Methods Numbers in red are NCCTG-Led Studies (4 ASCO GI) 3 2 9 6 7 7 15 13 6 5 3 3 4 4 2 2 49 42
  25. 25. CP1223393-25 Aim 1 Improved Therapeutics Future Plans THE PATIENT Targeted therapies Chemo- therapy Radiation Surgery Measure of Success Survival AND Quality of Life
  26. 26. CP1223393-26 Aim 2 Translational Research Future Plans THE PATIENT Patient Biology Pharmaco- genomics Immunology Tumor Biology Tumor tissue biomarkers
  27. 27. CP1223393-27 NCCTG High-quality science • Practice-changing therapies • Clinically meaningful translational results • Influential methodologic analyses • Active cancer control research Committed to collaboration • Community oncology and academic centers

×